These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35070018)

  • 21. Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis.
    Cao W; Zhao C; Shen C; Wang Y
    PLoS One; 2013; 8(12):e82092. PubMed ID: 24324749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome.
    Shengir M; Krishnamurthy S; Ghali P; Deschenes M; Wong P; Chen T; Sebastiani G
    World J Gastroenterol; 2020 Nov; 26(44):7046-7060. PubMed ID: 33311949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and Risks for Nonalcoholic Fatty Liver Disease and Steatohepatitis Post-liver Transplant: Systematic Review and Meta-analysis.
    Saeed N; Glass L; Sharma P; Shannon C; Sonnenday CJ; Tincopa MA
    Transplantation; 2019 Nov; 103(11):e345-e354. PubMed ID: 31415032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
    Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D;
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis.
    Eshraghian A; Nikeghbalian S; Kazemi K; Shamsaeefar A; Geramizadeh B; Malek-Hosseini SA
    HPB (Oxford); 2020 Apr; 22(4):521-528. PubMed ID: 31431413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease.
    Yilmaz Y; Eren F
    Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1292-5. PubMed ID: 25171027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease.
    Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
    Int J Clin Exp Med; 2014; 7(11):4191-8. PubMed ID: 25550930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic Fatty liver disease in renal transplant recipients proven by transient elastography.
    Mikolasevic I; Racki S; Lukenda V; Milic S; Pavletic-Persic M; Orlic L
    Transplant Proc; 2014 Jun; 46(5):1347-52. PubMed ID: 24836834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels.
    Zheng KI; Liu WY; Pan XY; Ma HL; Zhu PW; Wu XX; Targher G; Byrne C; Wang XD; Chen YP; Lu F; Zheng MH
    BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32139603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients.
    Sebastiani G; Saeed S; Lebouche B; de Pokomandy A; Szabo J; Haraoui LP; Routy JP; Wong P; Deschenes M; Ghali P; Klein M;
    AIDS; 2020 Feb; 34(2):237-244. PubMed ID: 31651429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
    Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
    Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
    Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
    World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic Variants in nicotinamide-N-methyltransferase (NNMT) gene are related to the stage of non-alcoholic fatty liver disease diagnosed by controlled attenuation parameter (CAP)-fibroscan.
    Hasan EM; Abd Al Aziz RA; Sabry D; Darweesh SK; Badary HA; Elsharkawy A; Abouelkhair MM; Yosry A
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):265-272. PubMed ID: 30240470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh.
    Alam S; Noor-E-Alam SM; Chowdhury ZR; Alam M; Kabir J
    World J Hepatol; 2013 May; 5(5):281-7. PubMed ID: 23717739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Okanoue T; Shima T; Mitsumoto Y; Umemura A; Yamaguchi K; Itoh Y; Yoneda M; Nakajima A; Mizukoshi E; Kaneko S; Harada K
    Hepatol Res; 2021 May; 51(5):554-569. PubMed ID: 33594747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis.
    Yang M; Xu D; Liu Y; Guo X; Li W; Guo C; Zhang H; Gao Y; Mao Y; Zhao J
    PLoS One; 2015; 10(6):e0131664. PubMed ID: 26121037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
    Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
    Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
    Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
    J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease.
    Younossi ZM; Stepanova M; Rafiq N; Henry L; Loomba R; Makhlouf H; Goodman Z
    Hepatol Commun; 2017 Jul; 1(5):421-428. PubMed ID: 29404470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.